Optimisation of blood glucose management is important for all patients with type 2 diabetes to improve both short-term and long-term health outcomes. General glycaemic targets have therefore been set for newly-diagnosed patients with uncomplicated diabetes at an HbA1c = 7% (53mmol/mol). Despite these guidelines for glycaemic management, however, over 60% of patients are reported as not reaching their glycaemic goals. One Australian study showed less than half of all patients with type 2 diabetes seen in general practice had an HbA1c = 7% (53 mmol/mol) while 25% had an HbA1c > 8% (64mmol/mol).
This activity is approved for 2 Core Point(s).
Associate Professor Michael d'Emden
MBBS, PhD, FRACP
Director of Endocrinology and Diabetes
Royal Brisbane Hospital
MBBS, MWell, DipRACOG
South Coast Medical
Blairgowrie, Victoria, Australia
On completion of this program, participants will be better able to:
- Identify patients who do not meet their individual HbA1c targets despite two oral diabetes medicines and require medication review to address the progressive nature of type 2 diabetes
- Evaluate which specific oral medications to add in order to improve HbA1c management and address co-morbidities
- Address the impact of pill burden on patients, as a means of improving adherence to diabetes medicines